CONFERENCE UPDATE: AAAAI 2023

Mepolizumab shows real-world benefits in patients with severe eosinophilic asthma and CRSwNP: The post-hoc analysis of REALITI-A

RESPIROLOGY
15 May 2023

Get access to our exclusive articles.
Related Articles

Dupilumab reduces the use of OCS and antibiotics in patients with CRSwNP in real-world practice

STUDY DESIGN  Dupilumab is indicated as an add-on maintenance treatment for adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).1 It has been shown to improve both objective and patient-reported outcomes in this population.1 However, data on dupilumab’s eff
RESPIROLOGY
13 Dec 2024

Symptom reduction and QoL improvement in CRSwNP patients with mepolizumab: Results from the phase 3 SYNAPSE trial

STUDY DESIGN Chronic rhinosinusitis with nasal polyp (CRSwNP) is a chronic disease characterized by elevated interleukin 5 (IL-5) levels and is often associated with severe sinonasal symptoms and nasal obstruction.1 Mepolizumab is a humanized anti-IL-5 antibody approved as an add-on medication for

08 May 2024